India markets closed
  • BSE SENSEX

    48,690.80
    -471.01 (-0.96%)
     
  • Nifty 50

    14,696.50
    -154.25 (-1.04%)
     
  • Dow

    34,269.16
    -473.66 (-1.36%)
     
  • Nasdaq

    13,389.43
    -12.43 (-0.09%)
     
  • BTC-INR

    4,129,037.50
    +24,131.00 (+0.59%)
     
  • CMC Crypto 200

    1,524.93
    +1,282.25 (+528.37%)
     
  • Hang Seng

    28,231.04
    +217.23 (+0.78%)
     
  • Nikkei

    28,147.51
    -461.08 (-1.61%)
     
  • EUR/INR

    89.0702
    -0.0700 (-0.08%)
     
  • GBP/INR

    103.7987
    +0.0854 (+0.08%)
     
  • AED/INR

    19.9480
    +0.0220 (+0.11%)
     
  • INR/JPY

    1.4772
    -0.0008 (-0.05%)
     
  • SGD/INR

    55.2870
    -0.0660 (-0.12%)
     

Solace Therapeutics Announces that Tri Valley Urology Enrolls First Patient in US Pivotal Clinical Trial, using New Office-Based Treatment for Female Stress Urinary Incontinence(SUI).

·2-min read

Tri Valley Urology, has enrolled their first patient in the VESAIR Clinical Trial. The VESAIR Clinical Trial is being conducted in several distinguished clinics throughout the US to test the safety and efficacy of the Vesair Bladder Control Balloon procedure.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210421005212/en/

(Photo: Business Wire)

"I am delighted to be participating in the VESAIR Clinical Study. SUI is not life-threatening, but if left untreated, it can greatly diminish a woman’s Quality of Life. Having a non-surgical option would be a great alternative for the nearly 1 in 2 women over the age of 50, who suffer from this condition" said Benjamin T. Larson, MD, Principal Investigator for the VESAIR Clinical Study.

About Stress Urinary Incontinence and the Vesair Bladder Control System

Women with Stress Urinary Incontinence(SUI) typically experience sudden increases in bladder pressure during physical movement, for example coughing, laughing, sneezing, or during exercise. When this increased bladder pressure exceeds the ability of the urethral sphincter to withstand pressure, leakage occurs. Unlike currently available SUI treatments that focus on improving the urethral closure force, the Vesair Bladder Control System is designed to reduce rapid increases in bladder pressure through the placement of a compressible air-filled balloon in the bladder. The balloon acts like a "shock-absorber" to slow rapid changes in pressure and reduce leakage. The uninflated balloon is placed into the bladder through the urethra and subsequently inflated. Balloon placement is performed during an in-office procedure that does not require anesthesia. When necessary, the balloon is deflated and removed in a similar in-office procedure. Most women manage their SUI with absorbent pads and are reluctant to undergo surgery for a variety of reasons. To learn more about the VESAIR Clinical Trial visit; www.vesairstudy.com.

About Solace Therapeutics, Inc.

Solace Therapeutics is an emerging women’s health company focused on a new office-based treatment for symptoms of female SUI. SUI is the most prevalent form of incontinence among women and affects an estimated 15 million adult women in the U.S. These women choose to manage their SUI by utilizing absorbent products such as protective pads versus seeking medical help. Solace is dedicated to improving the quality of life for women whose daily life is disrupted by their incontinence. Please visit www.solacetx.com to learn more about the company and review results from the first two clinical trials.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005212/en/

Contacts

Solace Therapeutics, Inc.
Nicole M. Shugrue, 508-283-1200 Ext. 165
Vice President, Marketing
nshugrue@solacetx.com